

Key Takeaways

- March saw the first major signs of market stress resulting from the record pace of central bank tightening over the past year.
- Emerging Markets delivered positive returns, following indications of support from the Chinese government towards the platform sector and cuts to the reserve requirement rate.
- The Antipodes Emerging Markets (Managed Fund) underperformed the benchmark over the month.

Commentary*

Global equities were up in March (+3.8%) with information technology, communication services and utilities outperforming whilst financials, energy and materials underperformed. US equities outperformed broader markets (+4.2%) despite concerns from the Silicon Valley Bank collapse. The Federal Reserve still hiked rates amongst concerns, although accompanied by a more dovish rhetoric as macroeconomic data weakened further. European equities underperformed (+3.1%) impacted by the Credit Suisse takeover over by UBS fuelling wider concerns around the banking sector. The ECB, Bank of England and Swiss National Bank all hiked rates as expected.

Asian equities also outperformed broader markets over the month (+4.4% in AUD) with limited impact from US and European banking sector concerns. Chinese equities

underperformed (+3.3%) despite the PBOC cutting the reserve requirement ratio for the first time in 2023 in an effort to further aid recovery. Large technology companies rallied on the government's show of support for the platform economy over the month. Japanese equities outperformed (4.7%) as core inflation data rose, with the BOJ continuing its yield curve control policy at least until the end of Kuroda's tenure.

Elsewhere, Brent Crude (-4.9% in USD) was lower, Gold (+7.8%) was strong as a safe haven, whilst the US Dollar (-2.3%) was weaker.


* Illustrative only and not a recommendation to buy or sell any particular security.

Net performance (%)


	1 month	3 month	CYTD	Inception
Fund	2.4	7.3	7.3	12.0
Benchmark	3.7	5.3	5.3	9.5
Difference	(1.3)	2.0	2.0	2.6

Past performance is not a reliable indicator of future performance. Returns are quoted in AUD and net of applicable fees, costs and taxes. All p.a. returns are annualised.

Top & bottom sector contribution^{1,2} (%)



Top & bottom stock contribution (%)



Market cap exposure³ (%)

Band	Weight	Benchmark
Mega (>\$100b)	31.5	26.4
Large (>\$25b <\$100b)	19.1	28.3
Medium (>\$5b <\$25b)	29.3	36.7
Small (<\$5b)	12.9	8.7

Sector exposure² (%)

Sector	Long	Benchmark
Consumer Discretionary	23.5	13.8
Financials	17.6	21.0
Information Technology	12.6	20.5
Communication Services	8.2	10.6
Consumer Staples	8.2	6.5
Industrials	7.9	5.9
Materials	6.7	8.7
Real Estate	4.2	1.8
Energy	3.9	4.7
Health Care	0.0	3.8
Utilities	0.0	2.6

Regional exposure^{3,4,5} (%)

Region	Long	Benchmark
Developing Asia	53.2	51.3
- China/Hong Kong	40.6	32.1
- Indonesia	5.7	1.9
- India	5.5	13.0
- Malaysia	0.9	1.4
- Rest EM Asia	0.6	2.8
LATAM/EEMEA	19.1	20.3
- Mexico	10.3	2.7
- Brazil	8.7	4.9
- Rest LATAM/EEMEA	0.0	12.8
Developed Asia	15.3	27.1
- Taiwan	7.8	15.1
- Korea	7.5	12.0
Rest of World	5.2	1.2
Total Equities	92.8	100.0
Cash	7.2	0.0
Totals	100.0	100.0

Top 10 equity longs³ (%)

Name	Country	Weight
Taiwan Semiconductor	Taiwan	6.1
Fomento Economico Mexicano	Mexico	4.8
Alibaba	China/HK	4.6
Ping An Insurance	China/HK	4.5
Samsung Electronics	Korea	3.8
Tencent	China/HK	3.6
Galaxy Entertainment Group	China/HK	3.4
PT Astra International	Indonesia	3.4
Country Garden Services Holdings Co.	China/HK	3.3
Petro Rio	Brazil	3.2

Fund facts

Characteristics	
Investment manager	Antipodes Partners Limited
Inception date	1 October 2022
Benchmark	MSCI Emerging Markets Index
Management Fee	1.20% p.a.
Performance Fee	15% of net return in excess of benchmark
Risk/Return profile	High
Buy/Sell spread	±0.30%
Minimum investment	\$25,000
Distributions	Annual, 30 June
Asset value	
Fund AUM	\$23m
Strategy AUM	\$23m
Unit redemption price	0.9774

Performance & risk summary⁶

	Portfolio	Benchmark
Standard deviation	27.7%	17.3%
Sharpe ratio	0.79	0.88
Information ratio	0.57	-
Beta	1.54	-
Stock count (long)	44	-
Average net exposure	77.5%	-
Upside capture ratio	149	-
Downside capture ratio	162	-

Fund features

- Objective to achieve absolute returns in excess of the benchmark over the investment cycle (typically 3-5 years)
- The Fund invests in companies that are exposed to emerging markets or listed on emerging market stock exchanges.
- In the absence of finding individual securities that meet minimum risk-return criteria, cash may be held to maximum 25%
- Flexibility to hedge for risk management purposes:
 - Currency exposure of the underlying stock position (net short currency position not permitted)
 - Equity market exposure via exchange traded derivatives (limited to 10% of NAV)
 - Leverage not permitted
- This product is likely to be appropriate for a consumer seeking capital growth to be used as a small allocation within a portfolio where the consumer has a minimum investment timeframe of 5 years, and a high risk/return profile.

Fund ratings



Further information

- 1300 010 311
- invest@antipodespartners.com

Australia head office

Antipodes Partners Limited
Level 35, 60 Margaret St
Sydney NSW 2000
Australia

UK Office

Antipodes Partners Limited
6th Floor, Nova North
11 Bressenden Place
London SW1E 5BY UK

¹ Based on gross returns in AUD

² GICS classification

³ Call (put) options represented as the current option value (delta adjusted exposure)

⁴ Antipodes classification

⁵ Where possible, regions, countries and currencies classified on a look through basis

⁶ All metrics are based on gross of fee returns in AUD terms since inception. The upside/downside capture ratio is the percentage of benchmark performance captured by the fund during months that the benchmark is up/down. Standard deviation is a measure of risk with a smaller figure indicating lower return volatility. The Sharpe ratio measures returns on a risk adjusted basis with a figure > 1 indicating a higher return than the benchmark for the respective levels of return volatility.

Disclaimer

This communication is prepared by Antipodes Partners Limited ('Antipodes') (ABN 29 602 042 035, AFSL 481580) as the investment manager of the Antipodes Emerging Markets (Managed Fund) (ARSN 096 451 393) ('the Fund'). Pinnacle Fund Services Limited ('PFSL') (ABN 29 082 494 362, AFSL 238371) is the product issuer of the Fund. PFSL is not licensed to provide financial product advice. PFSL is a wholly-owned subsidiary of the Pinnacle Investment Management Group Limited ('Pinnacle') (ABN 22 100 325 184). The Product Disclosure Statement ('PDS') and Target Market Determination ('TMD') of the Fund are available via below links. Any potential investor should consider the PDS and TMD before deciding whether to acquire, or continue to hold units in, the Fund.

Link to [Product Disclosure Statement](#)

Link to [Target Market Determination](#)

For historic TMD's please contact Pinnacle client service Phone 1300 010 311 or Email service@pinnacleinvestment.com

This communication is for general information only. It is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. It has been prepared without taking account of any person's objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. Past performance is for illustrative purposes only and is not indicative of future performance. Options exposure represents the market downside. For put options (typically used to limit potential downside) delta-adjusted exposure is used and for call options (typically used to capture potential upside) exposure is calculated using the current option value. Unless otherwise specified, all amounts are in Australian Dollars (AUD).

Whilst Antipodes, PFSL and Pinnacle believe the information contained in this communication is reliable, no warranty is given as to its accuracy, reliability or completeness and persons relying on this information do so at their own risk. Subject to any liability which cannot be excluded under the relevant laws, Antipodes, PFSL and Pinnacle disclaim all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information. This disclaimer extends to any entity that may distribute this communication.

Any opinions and forecasts reflect the judgment and assumptions of Antipodes and its representatives on the basis of information available as at the date of publication and may later change without notice. Any projections contained in this presentation are estimates only and may not be realised in the future.

Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained in this communication is prohibited without obtaining prior written permission from Antipodes. Pinnacle and its associates may have interests in financial products and may receive fees from companies referred to during this communication.

Zenith Disclaimer: The Zenith Investment Partners ('Zenith') (ABN 27 103 132 672, AFSL 226872) rating (assigned Antipodes Emerging Markets (Managed Fund) – November 2022) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at [Fund Research Regulatory Guidelines](#).

Lonsac Disclaimer: The Lonsac Rating (assigned May 2022) presented in this document is published by Lonsac Research Pty Ltd ('Lonsac') (ABN 11 151 658 561, AFSL 421445). The Rating is limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsac assumes no obligation to update the relevant documents following publication. Lonsac receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsac's Ratings methodology, please refer to our website at <https://www.lonsac.com.au/fund-manager/investment-product-ratings>.